Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 378

1.

Designing of CD8+ and CD8+-overlapped CD4+ epitope vaccine by targeting late and early proteins of human papillomavirus.

Kaliamurthi S, Selvaraj G, Kaushik AC, Gu KR, Wei DQ.

Biologics. 2018 Oct 2;12:107-125. doi: 10.2147/BTT.S177901. eCollection 2018.

2.

A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population.

Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Mutlu EA, Simsek I.

Biologics. 2018 Oct 2;12:97-106. doi: 10.2147/BTT.S172241. eCollection 2018.

3.

Focus on biosimilar etanercept - bioequivalence and interchangeability.

Cantini F, Benucci M.

Biologics. 2018 Aug 30;12:87-95. doi: 10.2147/BTT.S126854. eCollection 2018. Review.

4.

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway.

Pan YH, Jiao L, Lin CY, Lu CH, Li L, Chen HY, Wang YB, He Y.

Biologics. 2018 Aug 20;12:75-86. doi: 10.2147/BTT.S166867. eCollection 2018.

5.

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn's disease.

Matsumoto S, Mashima H.

Biologics. 2018 Jul 19;12:69-73. doi: 10.2147/BTT.S169326. eCollection 2018.

6.

The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation.

Hakimian S, Popov Y, Rupawala AH, Salomon-Escoto K, Hatch S, Pellish R.

Biologics. 2018 Feb 27;12:61-67. doi: 10.2147/BTT.S150958. eCollection 2018.

7.

New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.

Lundstrom K.

Biologics. 2018 Feb 9;12:43-60. doi: 10.2147/BTT.S140114. eCollection 2018. Review.

8.

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases.

Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F.

Biologics. 2018 Jan 31;12:37-41. doi: 10.2147/BTT.S145941. eCollection 2018.

9.

Analytical characterization of recombinant hCG and comparative studies with reference product.

Thennati R, Singh SK, Nage N, Patel Y, Bose SK, Burade V, Ranbhor RS.

Biologics. 2018 Jan 30;12:23-35. doi: 10.2147/BTT.S141203. eCollection 2018.

10.

Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.

Navalkele BD, Chopra T.

Biologics. 2018 Jan 18;12:11-21. doi: 10.2147/BTT.S127099. eCollection 2018. Review.

11.

Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice.

Chen YH, de Carvalho HM, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS.

Biologics. 2018 Jan 12;12:1-9. doi: 10.2147/BTT.S148606. eCollection 2018. Review.

12.

Anti-angiogenic effects of biotechnological therapies in rheumatic diseases.

Cantatore FP, Maruotti N, Corrado A, Ribatti D.

Biologics. 2017 Dec 14;11:123-128. doi: 10.2147/BTT.S143674. eCollection 2017. Review.

13.

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.

Yau H, Kinaan M, Quinn SL, Moraitis AG.

Biologics. 2017 Dec 6;11:115-122. doi: 10.2147/BTT.S108818. eCollection 2017. Review.

14.

Anticholinesterase constituents from the leaves of Spondias mombin L. (Anacardiaceae).

Elufioye TO, Obuotor EM, Agbedahunsi JM, Adesanya SA.

Biologics. 2017 Aug 2;11:107-114. doi: 10.2147/BTT.S136011. eCollection 2017.

15.

Epigenetic memory of oxidative stress: does nephrilin exert its protective effects via Rac1?

Mascarenhas DD, Herndon DN, Arany I.

Biologics. 2017 Jul 17;11:97-106. doi: 10.2147/BTT.S136188. eCollection 2017.

16.

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma.

Haldar P.

Biologics. 2017 Jun 27;11:81-95. doi: 10.2147/BTT.S93954. eCollection 2017. Review.

17.

Autophagy regulates the stemness of cervical cancer stem cells.

Yang Y, Yu L, Li J, Yuan YH, Wang XL, Yan SR, Li DS, Ding Y.

Biologics. 2017 Jun 21;11:71-79. doi: 10.2147/BTT.S134920. eCollection 2017.

18.

Paradoxical SAPHO syndrome observed during anti-TNFα therapy for Crohn's disease.

Amano H, Matsuda R, Shibata T, Takahashi D, Suzuki S.

Biologics. 2017 May 22;11:65-69. doi: 10.2147/BTT.S134508. eCollection 2017.

19.

Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties.

Talwar GP, Gupta JC, Mustafa AS, Kar HK, Katoch K, Parida SK, Reddi PP, Ahmed N, Saini V, Gupta S.

Biologics. 2017 May 2;11:55-63. doi: 10.2147/BTT.S128308. eCollection 2017. Review.

20.

CUL4A promotes cell invasion in gastric cancer by activating the NF-κB signaling pathway.

Gong Y, Xiang XJ, Feng M, Chen J, Fang ZL, Xiong JP.

Biologics. 2017 Apr 12;11:45-53. doi: 10.2147/BTT.S127650. eCollection 2017.

Supplemental Content

Loading ...
Support Center